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Reductions in plasma total cholesterol [−0.32 (±SD 0.70) 
mmol/L, p = 0.002], LDL cholesterol [−0.19 (±SD 0.56) 
mmol/L, p = 0.017] and triglycerides [−0.18 (±SD 0.48), 
p = 0.008] were also induced by OLE compared to control, 
whilst a reduction in interleukin-8 [−0.63 (±SD 1.13) pg/ml; 
p = 0.026] was also detected. Other markers of inflammation, 
vascular function and glucose metabolism were not affected.
Conclusion Our data support previous research, suggest-
ing that OLE intake engenders hypotensive and lipid-low-
ering effects in vivo.
Keywords Olive leaf · Polyphenols · Cardiovascular 
disease · Blood pressure · Plasma lipids · Oleuropein
Introduction
Consumption of the so-called Mediterranean diet has been 
associated with a decreased risk of chronic diseases, in par-
ticular cardiovascular disease (CVD), when compared to 
other dietary regimes [1, 2]. These effects may be attrib-
uted, in part, to the olive oil (OO) component of the diet [3]. 
Research comparing refined OO to extra virgin OO (EVOO) 
has highlighted the biological activity of the (poly)phenol 
components contained within the water-soluble fraction 
of EVOO [4, 5]. In addition to the fruit (from which OO is 
derived), the leaves of the olive plant (Olea europaea) also 
contain phenolic compounds at a much higher concentra-
tion than those of the olive fruit and oil (1450 mg total phe-
nolics/100 g fresh leaf [6] vs. 110 mg/100 g fruit [7] and 
23 mg/100 ml EVOO [8]). The most abundant phenolic 
compounds present in the leaves are verbascoside, apigenin-
7-glucoside, luteolin-7-glucoside, hydroxytyrosol (HT), tyro-
sol and the secoiridoid oleuropein, with secoiridoids being 
uniquely present in plants of the Oleaceae family [9].
Abstract 
Purpose Dietary polyphenols have been demonstrated to 
favourably modify a number of cardiovascular risk mark-
ers such as blood pressure (BP), endothelial function and 
plasma lipids. We conducted a randomised, double-blind, 
controlled, crossover trial to investigate the effects of a 
phenolic-rich olive leaf extract (OLE) on BP and a number 
of associated vascular and metabolic measures.
Methods A total of 60 pre-hypertensive [systolic blood 
pressure (SBP): 121–140 mmHg; diastolic blood pres-
sure (DBP): 81–90 mmHg] males [mean age 45 (±SD 
12.7 years, BMI 26.7 (±3.21) kg/m2] consumed either 
OLE (136 mg oleuropein; 6 mg hydroxytyrosol) or a poly-
phenol-free control daily for 6 weeks before switching to 
the alternate arm after a 4-week washout.
Results Daytime [−3.95 (±SD 11.48) mmHg, p = 0.027] 
and 24-h SBP [−3.33 (±SD 10.81) mmHg, p = 0.045] 
and daytime and 24-h DBP [−3.00 (±SD 8.54) mmHg, 
p = 0.025; −2.42 (±SD 7.61) mmHg, p = 0.039] were all 
significantly lower following OLE intake, relative to the control. 
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Data emanating from a number of studies suggest that olive 
leaf extract (OLE) may influence CVD risk via its potential 
to induce anti-atherosclerotic, hypotensive, antioxidant, anti-
inflammatory and hypocholesterolaemic effects (for review 
see [10]). The majority of these have been animal studies with 
limited data relating to effects in humans; however, human-
derived data have begun to appear in the literature. OLE has 
been reported to lower systolic blood pressure (SBP) and dias-
tolic blood pressure (DBP) from baseline in both hyperten-
sive and pre-hypertensive individuals [11–13] and to improve 
plasma lipid profiles in both normo-lipidaemic and hypercho-
lesterolaemic subjects [11, 13–15]. OLE has also been found 
to induce acute reductions in arterial stiffness compared to a 
control by our research group [16], which agrees with data 
suggesting that OO significantly improves vascular function 
[17–19] and blood pressure [20] and these improvements are 
specifically associated with phenolic-rich rather than phenolic-
poor OO [21]. In contrast, however, other studies have dem-
onstrated that OLE supplementation has no effect on plasma 
lipids [12, 22], ambulatory blood pressure (ABP), cytokines or 
carotid intima-media thickness [22].
In order to better understand the impact of OLE intake, 
and to address the inconsistent existing data, the current 
randomised, controlled, double-blind, crossover interven-
tion trial was designed to examine the effect of OLE on 
24-h ambulatory blood pressure (BP) and a range of related 
vascular, lipid and inflammatory markers in 60 pre-hyper-
tensive male volunteers.
Methods
Subjects and screening
A chronic human study was performed at the School of 
Food and Nutrition, Massey University, Auckland, New 
Zealand, from May–September 2013. The primary out-
come measure was BP. Secondary outcome measures were 
vascular function, arterial stiffness, plasma lipids, glucose, 
insulin, fructosamine, oxidised LDL, C-reactive protein 
(CRP), adiponectin, cell adhesion molecules and cytokines.
Power calculation
A mean reduction of 5mmHg in SBP was chosen as a clini-
cally significant end point, since at population level this has 
been estimated to relate to a 20 % reduction in CVD mor-
bidity and mortality [23]. To observe such a reduction using 
a crossover trial design with a standard deviation of 12.5 
mmHg in a normal population would require 50 subjects to 
be longitudinally studied with 90 % power and a significance 
value of 0.05. Eleven extra subjects were enrolled to allow for 
dropouts.
Volunteers were recruited for the study through advertise-
ments placed in local newspapers in the Auckland area and 
via flyers and posters on the Massey University campus as 
well as in shops and community buildings in the surrounding 
area. Email advertisements were sent to Massey University 
students and staff and those belonging to the IFNHH nutri-
tion unit volunteer database. Individuals who responded to 
advertisements were asked to complete a health and lifestyle 
questionnaire online or by telephone. Those who fitted the 
inclusion criteria were invited to the clinical unit for assess-
ment of further inclusion/exclusion criteria. Suitable sub-
jects were pre-hypertensive, non-smoking males, free from 
chronic disease, including cardiovascular disease, diabetes, 
cancer, inflammatory or digestive disorders. Asthmatics 
and those consuming more than 21 U/week of alcohol were 
excluded. Subjects were not taking anti-hypertensives, statins 
or other medication or dietary supplements that may affect 
BP, lipids or blood clotting, including fish oil. Pre-hyperten-
sive subjects were identified as those presenting with aver-
age SBP in the range 121–140 mmHg and/or average DBP 
in the range 81–90 mmHg at screening. Individuals with BP 
outside of these ranges were excluded. Subjects with food 
allergies or intolerances and those on a weight-reducing or 
restrictive diet (including vegetarian and vegan) were also 
excluded. Subjects arrived for screening fasted, and height 
and weight were measured using a stadiometer and Tanita 
weighing scales to calculate BMI. BP was measured after 
5-min rest, seated and with the subject’s left arm resting on a 
table, using an Omron digital BP monitor (HEM-907). Three 
readings were taken 60 s apart and averaged. Subjects were 
not permitted to talk during measurements. Mid-upper arm 
circumference (MUAC) was verified by tape measure in 
order to select the correct-sized BP cuff. A total of 61 suit-
able subjects were identified and accepted onto the trial.
Randomisation and blinding
Order of treatment allocation was done using the website ran-
domization.com using a random block design. Products were 
labelled by an external individual using four-digit random 
number codes in identical bottles made from opaque plastic. 
The treatment codes were kept offsite and not released until 
statistical analysis was complete. Therefore, allocation con-
cealment was achieved and both researchers and subjects were 
blinded to which product was being consumed at which time.
Study design
The study was a double-blind, randomised, controlled, 
crossover trial (Australia New Zealand Clinical Trials Reg-
istry number: ACTRN12613000180718, Clinicaltrials.
gov ID: NCT01796561, see Fig. 1 for study design). This 
study was conducted according to the guidelines laid down 
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in the Declaration of Helsinki, and all procedures involving 
human subjects were approved by the University of Read-
ing Research Ethics Committee (UREC 13/02). Written 
informed consent was obtained from all subjects. Sixty-
one subjects aged 24–72 years consumed liquid OLE sup-
plement or a control in a random order twice per day for 
6 weeks, separated by a 4-week wash out period, during 
which no product was consumed. Six weeks was chosen as, 
in relation to health claims for food products, the European 
Food Safety Authority states that ‘scientific evidence for the 
substantiation of health claims on the maintenance of nor-
mal blood pressure can be obtained from human interven-
tion studies showing a short-term (e.g. 3–4 weeks) reduc-
tion in systolic blood pressure, or a reduction in diastolic 
blood pressure’ [24]. Subjects avoided plant sterol-/stanol-
enriched spreads and all olive-containing products (olives, 
olive oil, olive margarine, tapenade) for the duration of the 
study (16 weeks). Clinical visits took place at weeks 0, 6, 10 
and 16 (before and after consuming each study product, four 
visits in total). Subjects refrained from consuming alcohol 
and taking part in strenuous exercise the day before study 
visits. The evening before study visits subjects consumed a 
standard low-fat meal of low phenolic content that was pro-
vided to participants (Weight Watchers macaroni cheese).
Intervention
The study product, ‘Olive leaf extract, extra strength’, is 
a commercially available, concentrated OLE liquid prod-
uct manufactured by Comvita, Limited (Paengaroa, Te 
Puke, New Zealand) and comprises vegetable glycerine 
and water in a 50:50 ratio plus olive leaf extract. The com-
mercial product is standardised to contain between 6.6 and 
7.9 mg oleuropein/ml; the batch used in this study con-
tained 6.81 mg oleuropein/ml and 0.32 mg HT/ml, provid-
ing 136.2 mg oleuropein and 6.4 mg HT per day. The full 
phenolic profile can be found in Table 1.
Subjects were instructed to consume 10 ml, twice per 
day, with food (20 ml per day in total) and were supplied 
with measuring cups and spoons. The control product com-
prised vegetable glycerine and water in a 50:50 ratio plus 
commercially available food colourings and flavourings 
in safety-approved quantities in order to match OLE as 
closely as possible on appearance, taste, texture and aroma.
n=121 screened for eligibility 
n=60 ineligible  
(SBP <120 or >140 and/or      
DBP <80 or >90) 
n=61 randomised 
Group A - 6 weeks OLE (n=31) 
1 dropout 
Group B - 6 weeks control (n=30) 
4 week washout – no product (n=60) 
Group A – 6 weeks control (n=30)  Group B – 6 weeks OLE (n=30) 
Analysed data  
n=60 
Fig. 1  Study flow
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Clinical visits
Subjects arrived for all clinical visits in a 12-h fasted state. 
Temperature was measured with an inner ear thermometer 
(Braun Thermoscan 6014) to check for the presence of 
acute infections. Subjects rested supine for 10 min before 
vascular function measurements began. Measurements 
were taken in a quiet room by a single trained operator. The 
SphygmoCor (AtCor Medical, Sydney) was used to meas-
ure pulse wave velocity (PWV). Pulse wave velocity has 
been validated and shown to be an independent predictor 
of cardiovascular mortality and morbidity [25]. The veloc-
ity at which pulse waves travel along arteries is dependent 
on the elasticity of the artery walls. PWV measures the 
amount of time taken for pressure waves to travel over a 
known distance and is calculated as the distance between 
the two positions of the pulse transducer divided by the 
time delay measured between pressure upstroke at each 
site. Here, PWV was recorded between carotid and femo-
ral artery sites. The pressure wave was recorded directly 
by means of a high-fidelity applanation tonometer which is 
a force recorder. The less elastic, or more stiff, the artery 
walls, the faster the velocity and the higher the PWV value 
[26]. Pulse wave analysis (PWA) is a non-invasive method 
which measures augmentation index (AIx), a manifesta-
tion of arterial stiffness. The method is sensitive to acute 
effects such as the ingestion of red wine [27] and black and 
green tea [28]. AIx is strongly correlated with PWV [29]. 
PWA was performed using the SphygmoCor, whereby a 
hand-held tonometry probe was used to flatten the subject’s 
radial artery. The SphygmoCor takes a 10-s snapshot of 
the arterial pressure wave and derives the ascending aortic 
pressure wave, measuring AIx. AIx indicates the augmenta-
tion of the incident pulse wave due to the reflection and is 
found by taking the difference between the first and sec-
ond derived aortic systolic peaks as a percentage of pulse 
pressure. AIx has been found to be influenced by heart rate 
[30] and so an index normalised for a heart rate of 75 bpm 
(AIx@75) was used here. Body composition was assessed 
via bioelectrical impedance using an InBody 230 analyser. 
Blood samples obtained via single venepuncture were col-
lected into heparin and EDTA vacutainers (BD).
Compliance measures
Subjects were asked to return all remaining bottles of study 
product at the end of each intervention period. Remaining 
liquid supplement was weighed and recorded. Subjects 
were asked to complete weekly online questionnaires and 
supplied with daily tick sheets.
Blood pressure
Twenty-four-hour ABP was assessed at weeks 0, 6, 10 and 
16 using automated monitors (Model TM-2430, Scan Med, 
A&D Medical, UK). Devices were programmed to meas-
ure BP every 30 min between the hours of 0700 and 2200 
and every 60 min between the hours of 2200 and 0700 with 
the cuff located on the upper left arm. In order to collect 
accurate data for a 24-h period, subjects were asked to wear 
the monitors for a duration of 25 h, and the first two read-
ings following fitting of the device were excluded to allow 
for subjects to adjust to the presence of the machine. Sub-
jects were asked to refrain from strenuous exercise whilst 
wearing the monitor and to keep the device on for the 
entire 25-h period, apart from when showering and dress-
ing, which was to be done between measurements. Subjects 
were instructed to use the BP monitors on a similar type of 
day to standardise for activity level, in particular to account 
for differences that may arise due to a work or non-work 
day. Subjects completed an activity diary and recorded 
sleep and wake times, which were used to classify data 
into ‘night’ and ‘day’ periods. Here, data collected within 
night and day periods were averaged, and an average of the 
whole 24-h period was also calculated.
Biochemical measures
Blood collected in EDTA and heparin vacutainers was cen-
trifuged at 1550×g for 15 min to separate plasma. Plasma 
was stored in low-binding Eppendorf tubes (Axygen, 
Tewksbury MA, USA) at −80 °C until analysis. Total cho-
lesterol (TC), HDL cholesterol (HDL-C), triglycerides 
(TAG), glucose and insulin were measured at North Shore 
Hospital, Auckland, in a Dimension Vista 1500 Intelligent 
Lab System. LDL cholesterol (LDL-C) was calculated 
using the Friedewald formula: [(LDL-C) = (TC) − (HDL-
C) – (TAG)/2.2]. QUICKI was calculated using the formula: 
1/(log insulin + log glucose). HOMA-IR was calculated 
Table 1  Phenolic composition of study product. Analysis performed 
via UPLC by product manufacturer (Comvita, Limited)
Phenolic compound mg/ml
Oleuropein 6.81
Oleoside 0.73
Hydroxytyrosol 0.32
Luteolin-7-O-glucoside 0.17
Tyrosol 0.12
Verbascoside 0.09
Apigenin-7-O-glucoside 0.07
Rutin 0.02
Vanillic acid 0.01
Vanillin 0.01
Luteolin 0.01
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using the formula: (glucose × insulin)/22.5. Fructosamine 
was measured using a colorimetric assay (Roche Cobas, 
Indianapolis, USA). Vascular cell adhesion molecule-1 
(VCAM-1), intercellular adhesion molecule-1 (ICAM-1), 
E-selectin, P-selectin, CRP and adiponectin were analysed 
using multiplex Luminex kits following standard instructions 
provided by the manufacturer (R&D). IL-6, TNF-α, IL-1-β, 
IL-10 and IL-8 were measured in a random subset of sub-
jects (mean age 42.3 ± 13.1 years) using an ultrasensitive 
multiplex Luminex kit (R&D). Oxidised LDL was measured 
in duplicate via an ELISA kit (Mercodia, Sweden). Plasma 
samples were analysed for nitrite and nitrate using chemilu-
minescence. Briefly, samples and standards containing nitrite 
and nitrate were first reduced to NO, which was then quan-
tified using an NO analyser (NOA Eco Physics chemilumi-
nescence detector, model 88 et). To determine total nitrite 
and nitrate concentrations, collectively termed ‘NOx’, sam-
ples were added to 0.1 mol/L vanadium (III) chloride in 1 M 
hydrochloric acid refluxing at 90 °C. Nitrite concentrations 
were determined by addition of samples to 1.1 % potassium 
iodide in glacial acetic acid under nitrogen at room tempera-
ture. Concentrations of nitrate were calculated by subtraction 
of nitrite from NOx values.
Statistical analysis
Statistical analysis was performed using SPSS statistics 
software version 21 (IBM) for data in which a complete 
set of four values (one per clinical visit) was available for a 
subject per variable. Data were checked for normality using 
the Kolmogorov–Smirnov and Shapiro–Wilk tests. Order 
of treatment effects was assessed using 2-way analysis of 
variance. Where there were no group × treatment interac-
tions present, whole group data were analysed. Significant 
group × treatment effects were indicated for fructosamine 
and IL-6 and so only data from visits 1 and 2 were used 
for these variables. Data were grouped by treatment, and 
difference values were calculated by subtracting the base-
line values from the end of treatment period values. Dif-
ference values from the two treatments were compared to 
each other using a paired Student’s t test. p values <0.05 
were deemed statistically significant.
Results
Compliance
One subject withdrew from the study after the first clinical 
visit due to relocation. There were no other dropouts, and 
60 subjects completed the study. Weighing of the remaining 
liquid OLE product revealed a compliance rate of 70.19 % 
(±SD 17.72) to OLE and 74.54 % (±SD 18.28) to the 
control. One subject experienced acne, and four subjects 
experienced mild stomach upset during the course of inter-
vention, but these symptoms were also experienced by sub-
jects on the control and did not result in subject withdrawal 
from the study.
Baseline characteristics of the subjects
All subjects were free from diagnosed chronic disease with 
a mean daytime BP of 139/83 mmHg (Table 2), classifying 
them as prehypertensive [31]. Average BMI was 26.7 kg/
m2, although subjects ranged from 20.4 to 37.4 kg/m2 
(healthy to obese). Subjects had total cholesterol, LDL-C 
and TC/HDL-C levels above that considered physiologi-
cally normal (5 mmol/L, 3.1 mmol/L and 4.3 vs. guideline 
values of <4  mmol/L, <2 mmol/L and <4, respectively 
[32]) (Table 2). Triglyceride and HDL-C concentrations 
were within the normal range (1.4 and 1.3 mmol/L vs. 
guideline values of <1.7 and ≥1 mmol/L).
Blood pressure and vascular function
Twenty-four-hour SBP, 24-h DBP and daytime SBP and 
DBP were all significantly reduced following intake of 
the OLE relative to control due to a decrease in BP after 
OLE consumption and an increase in BP after the con-
trol (Table 3). There were no significant differences 
between the effects of the two treatments on night time 
BP (Table 3). No significant impact of OLE on PWV was 
detected, although there was a tendency for OLE to attenu-
ate an increase in PWA-AI@HR75 after consumption of 
the control (p = 0.071) (Table 4).
Table 2  Baseline characteristics of the subjects
BMI body mass index, LDL low-density lipoprotein, HDL high-den-
sity lipoprotein, TC total cholesterol, SBP systolic blood pressure, 
DBP diastolic blood pressure
Variable Mean (SD)
Age (years) 45.3 (±12.7)
BMI (kg/m2) 27.0 (±3.4)
% body fat 22.5 (±6.6)
Total cholesterol (mmol/L) 5.0 (±1.0)
LDL cholesterol (mmol/L) 3.1 (±0.9)
HDL cholesterol (mmol/L) 1.3 (±0.4)
Triglycerides (mmol/L) 1.4 (±0.9)
TC/HDL cholesterol ratio 4.3 (±1.7)
Glucose (mmol/L) 5.2 (±0.4)
Insulin (mU/L) 8.9 (±5.8)
24-h SBP/DBP (mmHg) 135 (±11)/81 (±8)
Daytime SBP/DBP (mmHg) 139 (±12)/83 (±9)
Night time SBP/DBP (mmHg) 116 (±10)/68 (±8)
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Biochemical analysis and body composition
OLE intake significantly reduced plasma TC, LDL-C 
and TAG from baseline. Overall reductions relative to the 
control were 0.32, 0.19 and 0.18 mmol/L, respectively 
(Table 5). HDL-C significantly decreased from baseline 
following consumption of OLE; however, there were no 
significant effects on HDL-C or the LDL-C/HDL-C ratio 
compared to the control. There was a near-significant 
decrease in total cholesterol/HDL-C ratio following OLE 
consumption (p = 0.055) compared to the control (Table 5). 
There were no effects of OLE intake on fasting glucose, 
insulin, fructosamine or calculated HOMA-IR or QUICKI 
indices (Table 6). Similarly there was no effect on oxidised 
LDL, CRP, adiponectin, ICAM-1, VCAM-1, P-selectin, 
E-selectin, IL-6, IL-10, IL-1β or TNF-α (Table 7). How-
ever, OLE significantly reduced plasma IL-8 compared to 
the control (p < 0.05) (Table 7). There was no significant 
difference in plasma nitrite between the two groups (olive 
leaf change from baseline: 71.6 nM ± 801, n = 38; control 
change from baseline: 114 nM ± 732, n = 38). There was 
no impact of either treatment on body composition (see 
Supplementary Material Table S1).
Discussion
Previous studies have indicated potential blood pressure 
and lipid-lowering effects of OLE in humans, but results 
have thus far lacked consistency, perhaps due to differ-
ences in phenolic dose, duration and study design. Here, 
we provide data demonstrating that OLE has the potential 
to significantly reduce 24-h and daytime SBP and 24-h 
and daytime DBP relative to control. The magnitude of BP 
changes observed here (SBP by 3.33 and 3.95 mmHg and 
DBP by 2.42 and 3.00 mmHg (24 h and daytime values, 
respectively)) can be considered physiologically signifi-
cant. Data from observational studies suggest that 2 mm Hg 
reductions in SBP and DBP are associated with 6% and 7 
% reductions in CHD risk and 10% and 15 % reductions 
in stroke and heart attack respectively [33, 34]. Extrapolat-
ing from this would suggest that regular OLE intake may 
be associated with a 9–14 % reduction in CHD risk and a 
20–22.5 % reduction in risk of stroke and heart attack.
It has been postulated that oleuropein is the key hypoten-
sive component of OLE due to L-type Ca2+ channel antag-
onistic effects [35, 36]. In addition, verbascoside has been 
demonstrated to inhibit angiotensin-converting enzyme 
in vitro [37] as has oleacein [38]. With respect to oleuropein, 
our intervention provided 136 mg/day, compared to 200 mg/
day used in two previous studies; which resulted in mean 
reductions in systolic and diastolic blood pressure of 13 and 
5 mmHg, respectively, in pre-hypertensive MZ twins [11] Ta
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Table 4  Effect of OLE on vascular function measures
Data points are mean ± SD
OLE olive leaf extract, PWV pulse wave velocity, PWA-AI@HR75 pulse wave analysis-derived augmentation index corrected to a heart rate of 
75 bpm
* End value was significantly different from baseline value, paired Student’s t tests
‡ Values derived from paired Student’s t tests comparing OLE mean change values with control mean change values
Variable OLE Control OLE versus  
control mean  
difference (SD)
n p‡
Baseline End Mean change 
(SD)
Baseline End Mean change  
(SD)
PWV (m/s) 9.35 (±1.94) 9.06 (±1.54) −0.29 (±1.41) 9.45 (±1.71) 8.97 (±1.86) −0.48 (±1.58)* 0.19 (±1.91) 54 0.461
PWA-AI@
HR75 (%)
10.19 (±12.67) 11.37 (±12.28) 1.19 (±5.92) 9.54 (±11.96) 12.94 (±10.62) 3.41 (±3.41)* −2.22 (±8.86) 54 0.071
Table 5  Effect of OLE on fasting plasma lipids
Data points are mean ± SD
OLE olive leaf extract, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TAG triglycerides, TC total cho-
lesterol
* End value was significantly different from baseline value, paired Student’s t tests
‡ Values derived from paired student’s t tests comparing OLE mean change values with control mean change values
Variable OLE Control OLE versus  
control mean  
difference (SD)
n p‡
Baseline End Mean change 
(SD)
Baseline End Mean change 
(SD)
Total cholesterol 
(mmol/L)
5.11 (±0.99) 4.78 (±0.99) −0.33 (±0.47)* 5.02 (±1.02) 5.00 (±0.97) −0.01 (±0.44) −0.32 (±0.70) 52 0.002
LDL-C  
(mmol/L)
3.14 (±0.88) 2.94 (±0.87) −0.20 (±0.41)* 3.09 (±0.90) 3.08 (±0.89) −0.01 (±0.37) −0.19 (±0.56) 52 0.017
HDL-C  
(mmol/L)
1.29 (±0.40) 1.24 (±0.34) −0.05 (±0.18)* 1.30 (±0.38) 1.29 (±0.38) −0.007 (±0.17) −0.04 (±0.24) 52 0.202
TAG (mmol/L) 1.48 (±0.87) 1.30 (±0.77) −0.18 (±0.46)* 1.39 (±0.88) 1.40 (±0.84) 0.004 (±0.51) −0.18 (±0.48) 52 0.008
LDL-C/HDL-C 
ratio
2.68 (±1.18) 2.58 (±1.12) −0.09 (±0.42) 2.61 (±1.16) 2.63 (±1.16) 0.02 (±0.39) −0.12 (±0.54) 52 0.125
TC/HDL-C ratio 4.32 (±1.72) 4.16 (±1.63) −0.16 (0.54)* 4.22 (±1.73) 4.24 (±1.74) 0.03 (±0.44) −0.19 (±0.70) 52 0.055
Table 6  Effect of OLE on measures of glucose metabolism
OLE olive leaf extract, HOMA-IR homoeostasis model assessment-estimated insulin resistance, QUICKI quantitative insulin sensitivity check 
index
‡ Values derived from paired Student’s t tests comparing OLE mean change values with control mean change values
§ Significant treatment × sequence interactions were shown for this variable; therefore, only data derived from the first intervention period 
(week 0–week 6) are reported
Variable OLE Control OLE versus 
control mean 
difference (SD)
n p‡
Baseline End Mean change 
(SD)
Baseline End Mean change 
(SD)
Glucose 
(mmol/L)
5.32 (±0.44) 5.27 (±0.54) −0.05 (±0.37) 5.28 (±0.46) 5.33 (±0.43) 0.05 (±0.32) −0.10 (±0.52) 52 0.163
Insulin (mU/L) 9.46 (±6.1) 8.86 ±(5.25) −0.60 (±4.50) 9.27 (±5.73) 9.97 (±7.49) 0.70 (±5.15) −1.30 (±7.19) 52 0.197
HOMA-IR 2.28 (±1.57) 2.13 (±1.45) −0.15 (±1.18) 2.25 (1.64) 2.42 (1.96) 0.17 (±1.21) −0.32 (±1.80) 52 0.483
QUICKI 0.63 (±0.10) 0.64 (±0.09) 0.01 (±0.07) 0.63 (±0.11) 0.63 (±0.12) −0.002 (±0.07) 0.01 (±0.10) 52 0.482
Fructosamine§ 
(µmol/L)
230.41 
(±18.04)
221.24 
(±15.94)
−9.17 (±13.19) 229.29 
(±14.30)
222.48 
(±15.17)
−6.81 (±14.82) −2.36 29, 31 0.517
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and 12 and 5 mmHg, respectively, in hypertensive patients 
[13] a magnitude of effect similar to that of Captopril, a 
common anti-hypertensive drug [13]. In a further study, a 
dose of 51 mg oleuropein/day induced no significant reduc-
tions in BP [22] although this study tested OLE capsules, 
which may be less bioavailable than the liquid used in the 
current study [39]. Assuming linearity between dose and 
BP reductions, our prescribed dose would be expected to 
yield a reduction of approximately 8 mmHg, higher than 
that measured in our study. However, as our compliance 
rate was 70.19 % with respect to OLE consumption, daily 
oleuropein intake can be estimated to be lower at around 
95 mg oleuropein per day. Furthermore, we employed 24-h 
ambulatory BP measures in our study, which arguably pro-
vide more robust information on BP compared to the single 
measures used in the aforementioned studies [40]. Studies 
examining the effects of OO phenolics and their metabo-
lites suggest that these may influence NO production in vivo 
[41], or scavenge ROS in the vasculature [42], following 
their appearance in the circulation. Whilst previous studies 
have linked the phenolic content of OO with increases in 
nitric oxide and ultimately clinical outcomes [20, 43], we 
observed no significant impact on circulating nitrites. It is 
possible that nitrite contamination from the use of samples 
collected in EDTA tubes lead to the high standard deviation 
of this data and masked any changes that occurred. Addi-
tionally, it is noteworthy that the product used here has not 
been completely characterised meaning that other bioactives 
aside from polyphenols, such as minerals, squalene and, trit-
erpenoids such as oleanolic, ursolic and maslinic acids [44], 
could have been responsible for the observed blood pres-
sure effects, thus pointing towards a different mechanism of 
action besides NO. For example, African olive leaf cultivars 
which are triterpenoid-rich and polyphenol-poor have been 
reported to prevent hypertension and atherosclerosis and 
improve insulin resistance in Dahl salt-sensitive rats [45].
With arguably more pronounced effects than on BP, 
OLE intake was also associated with physiologically signif-
icant reductions in TC, LDL-C and TAG of 0.32, 0.19 and 
0.18 mmol/L, respectively, when compared to the control, 
with no detrimental effect on HDL-C. Considering previous 
trials conducted with statins, the TC and LDL-C reductions 
reported in the present study could equate to an overall 
CVD risk reduction of 4.2 % [46] and 9.75 % [47], respec-
tively. Similarly, data from a meta-analysis of population-
based prospective cohort studies report that a 1 mmol/L 
increase in TAG results in a 32 % CHD risk increase. On 
this basis, consumption of OLE at the dose provided in 
our study may promote a 5.76 % CHD risk reduction [48]. 
Data regarding the effects of OLE on plasma lipids have 
been somewhat inconsistent. For example, in a study of 20 
MZ twin pairs, a 200 mg/day intake of oleuropein resulted 
in a 0.6 mmol/L decrease in TC, a 0.4 mmol/L decrease in 
LDL cholesterol and no change in TAG relative to healthy 
lifestyle advice alone after 8 weeks, whilst a 100 mg/day 
dose had no significant effects on lipids [11], whereas 
a larger study (n = 148) found less efficacious changes 
of −0.15 mmol/L in TC, −0.10 mmol/L in LDL-C and 
−0.13 mmol/L in TAG [13]. A more recent study reported 
decreases of 0.68, 0.90 and 0.047 mmol/L in TC, LDL-C 
and TAG, respectively (with a non-significant increase in 
HDL-C), after 12 months consumption of a supplement 
containing 100 mg oleuropein [15], providing some evi-
dence of sustained and larger effects over longer periods of 
time. Individual differences in the absorption and metabo-
lism of OLE phenolics could be responsible [39].
The mechanisms underlying the lipid-lowering effects of 
OLE are presently unknown. However, animal data suggest that 
the consumption of phenolic components of OLE appears to 
decrease the activities of key cholesterol-regulatory enzymes, 
3-hydroxy- 3-methylglutaryl-CoA (HMG-CoA) reductase (the 
main target of statins) and acetyl-CoA cholesterol acyltrans-
ferase (ACAT), resulting in decreased cholesterol biosynthesis 
[49]. Additional animal data suggest that olive phenolics may 
impact on bile flow, increasing biliary cholesterol and bile acid 
concentrations, leading to their increased faecal excretion [50]. 
Interestingly, a recent paper reporting favourable modification 
of lipid profiles by OLE [15] also observed osteoblast stimula-
tion and hypothesised that as osteoblasts and adipocytes derive 
from the same mesenchymal stem cells, this may explain the 
change in lipid profiles. Once again, there is evidence to sug-
gest that non-phenolic components may contribute to lipid-
lowering effects [51].
Chronic OLE intake reduced plasma IL-8 concentra-
tion in a subgroup of the subjects (n = 19). Due to the 
high natural variability of cytokine production, greater 
power may be required for reliable and meaningful data 
[52]. When accounting for multiple comparisons of inflam-
matory markers, the result is no longer significant (a p 
value < 0.004 would be needed to be statistically significant 
[0.05/12 comparisons (12 inflammatory markers)]; how-
ever, the finding reflects our previous data, indicating that 
an acute dose of OLE decreases ex vivo production of LPS-
stimulated IL-8 (but not other cytokines) in whole blood 
cultures [16]. Anti-inflammatory effects of OLE are also 
indicated by its use in a patented haemorrhoid treatment 
[53], and from data demonstrating that OLE phenolics 
reduce inflammatory cytokines in animal [54] and ex vivo 
[55] studies [22]. IL-8 is associated with increased risk of 
future CVD incidences [56], perhaps through its ability to 
destabilise existing atherosclerotic plaques by down-regu-
lation of tissue inhibitors of metalloproteinase expression 
[57]. However, cytokines lack the robustness of other CVD 
biomarkers such as blood pressure and plasma lipids, and it 
is difficult to attribute clinical importance to reductions in 
these markers [58].
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The effect of OLE on glycaemic control was worthy of 
investigation as chronic OLE supplementation has been 
related to improvements in an oral glucose tolerance test 
and additionally 1 g olive leaf fed with 300 g white rice 
has been observed to significantly reduce blood glucose 
at 30 and 60 min in borderline diabetics [22, 59]. In both 
instances, these effects were thought to be mediated by the 
inhibitory action of OLE polyphenols on intestinal and/or 
salivary α-amylases; however, it is also possible that OLE 
aglycones compete with glucose released from food in 
the gut for glucose receptors, resulting in less absorption. 
In the present study, there were no significant effects of 
OLE on fasting glucose, insulin, fructosamine, QUICKI or 
HOMA-IR indices. In line with this, a previous study has 
indicated no change in fasting glucose after 3-week VOO 
supplementation compared to refined OO [60].
Conclusion
The present study has strengthened the existing body of 
evidence that OLE has the potential to favourably modify 
blood pressure and plasma lipid profiles. The magnitude 
of the risk-lowering potential we describe could have sig-
nificant impact at population level in countries with high 
prevalence of CVD. The impact of dietary factors towards 
CVD risk has informed the provision of a diet rich in fruit 
and vegetables in the primary prevention of hypertension 
and raised cholesterol [61, 62]. In the near future, there 
may be enough evidence for this advice to be extended to 
include phenolic-rich foods. Daily consumption of OLE 
can result in favourable improvements in several CVD risk 
factors which could result in a moderate but nonetheless 
significant reduction in risk, making it a useful addition to a 
healthy diet and lifestyle.
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